Stüve Olaf
Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, TX 75216, USA.
J Neurol Sci. 2008 Nov 15;274(1-2):39-41. doi: 10.1016/j.jns.2008.03.022. Epub 2008 May 12.
Multiple sclerosis (MS) is an inflammatory demyelinating disorder of the central nervous system (CNS). Natalizumab ((R)Tysabri) is a humanized recombinant monoclonal antibody that binds to the alpha (alpha)(4) chain of the alpha(4) beta (beta)(1) integrin (very late activation antigen 4; VLA-4), and alpha(4)beta(7) integrin. Recently, two patients with MS and one patient with Crohn's disease who were treated with natalizumab in the setting of clinical trials developed progressive multifocal leukoencephalopathy (PML), an opportunistic infection of the brain with the polyoma virus JC. We recently showed that natalizumab decreases the numbers of CD4(+) and CD8(+) T lymphocytes, CD19(+) B cells, and CD138(+) plasma cells in the cerebrospinal fluid (CSF) of patients with MS on natalizumab therapy. In addition, we demonstrated that the cell numbers in CSF remained unchanged even 6 months after cessation of natalizumab treatment.
多发性硬化症（MS）是一种中枢神经系统（CNS）的炎性脱髓鞘疾病。那他珠单抗（（R）泰萨比）是一种人源化重组单克隆抗体，可与α4β1整合素（极晚期活化抗原4；VLA - 4）的α4链以及α4β7整合素结合。最近，在临床试验中接受那他珠单抗治疗的两名MS患者和一名克罗恩病患者发生了进行性多灶性白质脑病（PML），这是一种由多瘤病毒JC引起的脑部机会性感染。我们最近发现，那他珠单抗可减少接受那他珠单抗治疗的MS患者脑脊液（CSF）中CD4⁺和CD8⁺T淋巴细胞、CD19⁺B细胞以及CD138⁺浆细胞的数量。此外，我们还证明，即使在停止那他珠单抗治疗6个月后，CSF中的细胞数量仍保持不变。
